OncoMatch/Clinical Trials/NCT06778603

B7-H3 NIR Imaging for Osteosarcoma Surgery

Is NCT06778603 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies a targeted probe B7H3-IRDye800CW for osteosarcoma.

Phase 1/2RecruitingPeking University People's HospitalNCT06778603Data as of May 2026

Treatment: a targeted probe B7H3-IRDye800CW — Complete removal of all tumor tissue with a wide surgical margin is essential for the treatment of osteosarcoma (OS). However, it's difficult, sometimes impossible, to achieve due to the invisible small satellite lesions and blurry tumor boundaries. Besides, intraoperative frozen-section analysis of resection margins of OS is often restricted by the hard tissues around OS, which makes it impossible to know whether a negative margin is achieved. Herein, based on the high expression of B7-H3 in OS, a targeted probe B7H3-IRDye800CW is synthesized by conjugating anti-B7H3 antibody and IRDye800CW. This trial is aimed to investigate R0-resection rate and 2-y local recurrence rate after using this probe in Musculoskeletal tumor surgery for osteosarcoma as well as the safety parameters of this probe in human.

Check if I qualify

Extracted eligibility criteria

Cancer type

Osteosarcoma

Prior therapy

No prior treatment (treatment-naive required)

Max 0 prior lines

Cannot have received: radiation therapy

Exception: to the target lesion

Prior radiation therapy to the target lesion

Lab requirements

Blood counts

adequate bone marrow function

Kidney function

adequate renal function

Liver function

adequate liver function

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify